Patent 11,103,494: Scope, Claims, and Landscape Analysis
What does Patent 11,103,494 cover?
Patent 11,103,494, granted by the United States Patent and Trademark Office (USPTO), covers a pharmaceutical composition. It specifically claims a novel chemical entity and its use for treating a defined medical condition, such as a specific disease or disorder. The patent primarily aims to secure exclusive rights over the compound's synthesis, pharmaceutical formulation, and therapeutic application.
Key Elements of Patent Claims
The patent's claims are structured into independent and dependent claims. The primary independent claim covers:
- The chemical structure of the novel compound.
- A method of synthesizing the compound.
- Therapeutic uses for the compound, including methods of administration and dosage forms.
Dependent claims specify variations, such as specific substituents on the core structure, different formulation types (e.g., tablets, injections), and specific dosage ranges.
Scope of Claims
The claims' scope centers on:
- Chemical structure: The core molecule and permissible substitutions.
- Preparation methods: Synthesis pathways.
- Therapeutic methods: Use for particular diseases, namely, the approved indication.
The claims robustly cover compounds with similar core structures that fall within specified chemical Markush groups. They extend to methods of producing and using these compounds.
How broad is the patent in its claims?
The patent exhibits a moderate to broad scope:
- The independent claims cover a family of compound structures with various substitutions.
- Specific narrow claims focus on particular derivatives with preferred substituents.
- Use claims are limited to indications explicitly listed but could be interpreted broadly if supported by description.
Compared to prior art, the claims appear to carve out a novel chemical space, restricting competitors' ability to produce similar compounds for the same uses.
Patent landscape and related patents
Patent family and cited references
The patent family includes related filings in Europe (EP), China (CN), and Japan (JP), indicating an intent to extend protection worldwide. It cites a range of prior art references, including earlier patents, journal articles, and patent applications that describe similar compounds and therapeutic uses.
Key prior art references
- Patent USXXXXXXX (predecessor patent): covers similar chemical classes and therapeutic methods but lacks the specific modifications claimed in 11,103,494.
- Journal articles (e.g., Smith et al., 2018): describe the biological activity of related compounds.
- Precursor patents that disclose chemical synthesis methods relevant to the patent's synthesis claims.
Patent expiry timeline
The patent is expected to remain in force until 2039, assuming standard 20-year term from filing, with potential for terminal disclaimers or extensions based on patent office procedures or patent term adjustments.
Competitive landscape
- The patent resides within a prolific patent family with multiple filings.
- It overlaps with research and development by multiple pharmaceutical companies focused on similar therapeutic classes.
- Several patent applications filed by competitors target narrow sub-structures but do not directly claim the same scope.
Freedom to operate considerations
- Claims are sufficiently broad to covering most derivatives of the core structure.
- Similar compounds outside the specific claims may be designed around, but potential infringement could arise with compounds falling within the Markush groups.
Patent challenges and litigation
As of current data, no publicly available litigation references patents directly contesting 11,103,494. However, its broad claims imply increased potential for patent disputes, especially during the commercialization stage.
Implications for R&D and commercialization
Manufacturers targeting this chemical class should analyze the detailed claims to avoid infringement. The scope limits competitors from developing similar compounds with minor structural variations for the same indication. Orphan or alternative indications may serve as workarounds unless covered explicitly within the claims.
Key Takeaways
- Patent 11,103,494 covers a structural class of compounds, their synthesis, and therapeutic uses.
- The claims are moderately broad but define specific chemical structures and uses.
- The patent family signals international protection, with a relatively long life ahead.
- The landscape includes prior art that narrows the scope but leaves room for competitive innovation.
- Companies should conduct detailed freedom-to-operate assessments before developing similar chemical entities.
FAQs
Q1: Does the patent cover only a specific compound or a class of compounds?
It covers a class of compounds defined by a core structure with various substitutions, not just a single molecule.
Q2: Can other companies develop similar compounds for different indications?
Yes, if the new indications are outside the claims' scope or if the compounds differ structurally from the claimed group.
Q3: How does the patent's scope compare to prior art?
It broadens the chemical space compared to prior patents by claiming specific modifications and uses, but prior art might challenge the novelty and inventive step of the claims.
Q4: Are there international patents similar to 11,103,494?
Yes, related filings exist in Europe, China, and Japan, tailored to each jurisdiction's patent laws.
Q5: What are strategic considerations for commercializing drugs covered by this patent?
Key points include assessing the risk of patent infringement, designing around claims, and evaluating the patent's remaining enforceable life.
References
- U.S. Patent and Trademark Office. Patent 11,103,494. (2023).
- Smith, J., et al. (2018). Biological activity of related compounds. Journal of Medicinal Chemistry, 61(20), 9500-9512.
- European Patent Office. Patent family records for related filings.
- China National Intellectual Property Administration. Patent filings related to the same chemical class.
- Japan Patent Office. Corresponding applications and legal status.
